Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 and FOLFOX in Advanced Metastatic Colorectal Cancer
NCT02041481Phase 1Completed
- Sponsor
- City of Hope
- Start
- Jul 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of binimetinib in colorectal cancer (CRC) (2 arms), sponsored by City of Hope. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Dose-Limiting Toxicity at 4 weeks. Started Jul 2014; status: completed.
02
Drugs
binimetinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02041481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02041481.